💊Sumitomo Dainippon Pharma Completes Manufacturing Plant for Regenerative Medicine & Cell Therapy

By IPS, Pharmaceutical

💊Sumitomo Dainippon Pharma Completes Manufacturing Plant for Regenerative Medicine & Cell Therapy

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director,
President and CEO: Masayo Tada) announced today the completion of the Sumitomo Dainippon
Manufacturing Plant for Regenerative Medicine & Cell Therapy (“SMaRT”; hereinafter, the “Plant”)
at its Central Research Laboratories (Suita City, Osaka).

http://www.ds-pharma.com/ir/news/pdf/ene20180301.3.pdf

More from tokioX :

  1. Kyoto Univ’s Center for iPS Cell Research and Application, Sumitomo Chemical, and Sumitomo Dainippon Pharma Commence Joint Research on Producing Higher-Quality iPS Cells for Clinical Use
  2. Hitachi Zosen: Development and sale of “Sterilization / Decontamination Pass Box” for Sterilization for  Regenerative Medicine
  3. 🏭Developed a new type automatic cell culture system “AUTO CULTURE” to expand the spread of regenerative medicine
  4. 🏥Cell and Gene Therapy Catapult enters into partnership with the Japanese Society for Regenerative Medicine
  5. 💊SUMITOMO DAINIPPON PHARMA CO., LTD. Filed Additional Patent Infringement Lawsuit Regarding LATUDA in the United States
  6. 💊FDA PHARMA TODAY
  7. 💊Sumitomo Dainippon Pharma Announces an Atypical Antipsychotic LONASEN is Now Available in China